PATENT CLAIM ANALYSIS

Application Number: 16025302
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["435", "455000"]

Abstract:
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.

Claim (Index 8):
The composition of  claim 1 , wherein the relaxin protein has a nucleotide sequence that is 70%-100% identical to the sequence of SEQ ID NO. 1.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 95.0
- Lexical Diversity: 1.78689
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15846084', '16005286', '16002472', '16002376', '15476253']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6984212260320495
- 35 USC 102 Novelty (BERT): 0.5655300944597729
- Combined Prediction Score: 0.6851321128748219
- Mean Citation Score: 483.315236
- Max Citation Score: 503.25265999999993
- Similarity Product: 322.12398983731737

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test